Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents
Abstract
A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminescent cyclometalated iridium(III) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.
Fetching data from CrossRef.